Superworth

Prothena Corp Public price to book ratio PRTA

Market value divided by the book value of the company's net assets, since 2013.

Today, Oct 23, 2026
1.5×
10-year median
2.2×
Against its 10-year history
20th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.6× to 12.0×
Peer median
1.9×

Prothena Corp Public's price to book ratio is 1.5× as of Oct 23, 2026.

That is below its ten-year median of 2.2×, lower than on 80% of days in the last ten years.

Over that time it ranged from 0.6× in May 2025 to 12.0× in Sep 2021.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.5×1.4×2.1×
20251.7×0.6×2.0×
20241.5×1.3×3.5×
20233.2×2.9×6.9×
20227.2×2.5×7.8×
20214.7×2.1×12.0×
20202.3×1.3×2.5×
20192.2×0.9×2.2×
20181.2×1.0×3.9×
20173.2×3.2×5.4×
20164.2×2.6×5.6×
20155.7×1.8×7.4×
20141.9×1.6×8.0×
20136.0×1.5×6.2×

Against its peers

Companies in Drug Manufacturers - General nearest Prothena Corp Public's size, closest first, today.

CompanyPrice to book ratio
PRTAProthena Corp Public1.5×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
NATRNatures Sunshine Products1.3×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Prothena Corp Public

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.